Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | FABP3 | P05413 | 1/20 | 0.35 |
| ▸ | FABP1 | P07148 | 1/20 | 0.35 |
| ▸ | FABP4 | P15090 | 1/20 | 0.35 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.35 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6821916 | 0.92 | ADORA1 (0.42) | NPC1RAB9AADORA1SMN1; SMN2FABP3 | |
| SCHEMBL6822492 | 0.91 | ADORA1 (0.38) | NPC1RAB9AADORA1LMNAFABP3 | |
| SCHEMBL6818702 | 0.90 | ADORA1 (0.46) | ADORA1FABP3FABP1FABP4FABP5 | |
| SCHEMBL6822276 | 0.89 | ADORA1 (0.46) | NPC1RAB9AADORA1FABP3FABP1 | |
| SCHEMBL6822058 | 0.89 | ADORA1 (0.42) | ADORA1LMNACMKLR1PTGER1 | |
| SCHEMBL6822546 | 0.85 | ADORA1 (0.41) | ADORA1CMKLR1 | |
| SCHEMBL6822503 | 0.85 | ADORA1 (0.41) | ADORA1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL6821896 | 0.85 | SMN1; SMN2 (0.43) | NPC1RAB9AADORA1SMN1; SMN2LMNA | |
| SCHEMBL6822553 | 0.85 | ADORA1 (0.38) | ADORA1SMN1; SMN2LMNATSHRALDH1A1 | |
| SCHEMBL6822138 | 0.85 | ADORA1 (0.45) | ADORA1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110763-A1 | Pyrazolopyridine compound and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110763-A1 | Pyrazolopyridine compound and pharmaceutical use thereof | ADRB1, ADRA1D, ADRB3 | NPC1 1281/4885RAB9A 1138/4885ADORA1 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.